- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- August 2020
- 120 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- August 2022
United States
From €1872EUR$1,940USD£1,606GBP
- Report
- August 2022
Global
From €763EUR$790USD£654GBP
- Report
- February 2021
Global
From €2857EUR$2,960USD£2,451GBP
- Report
- December 2021
- 130 Pages
Global
From €10612EUR$10,995USD£9,103GBP
- Report
- September 2021
- 49 Pages
Global
From €3856EUR$3,995USD£3,308GBP
- Clinical Trials
- January 2020
- 498 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- October 2020
- 134 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- July 2022
- 128 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- June 2023
- 132 Pages
Global
From €917EUR$950USD£787GBP
- Report
- February 2023
- 268 Pages
Global
From €5531EUR$5,730USD£4,744GBP
The Bladder Drug market is a subset of the Urological Disorders Drugs market, which focuses on treatments for conditions related to the urinary tract. These drugs are used to treat a variety of conditions, including urinary incontinence, overactive bladder, bladder cancer, and urinary tract infections. Bladder drugs are typically administered orally, topically, or through injections. Commonly prescribed bladder drugs include anticholinergics, antispasmodics, and alpha-blockers.
The Bladder Drug market is highly competitive, with a range of generic and branded products available. Companies in the market include Astellas Pharma, Allergan, Pfizer, Merck, and Sanofi. Show Less Read more
